• Home
  • About Us
  • Team Members
  • News
  • Careers
    • Apply Now
  • Contact Us
NuShores BiosciencesNuShores Biosciences
  • Home
  • About Us
  • Team Members
  • News
  • Careers
    • Apply Now
  • Contact Us

NuShores BioSciences attracts medical devices manufacturing professional to Little Rock

July 13, 2020

Mark Pelo will lead NuShores’ production of NuCress™ bone regenerative product line.

Little Rock, AR – NuShores Biosciences LLC (NuShores), founded and based in Little Rock, Arkansas, announced today that Mr. Mark Pelo has accepted the position of Manufacturing Manager and will move to Little Rock from the Pittsburgh area. He will lead NuShores Generation 1 manufacturing of NuCress™ bone void filler scaffold products and serve as the Program Director and Principal Investigator on new and pending manufacturing projects to automate the company’s production systems.


Mark is a manufacturing leader with a reputation as inventive and accomplished in medical device and biologic device manufacturing process development engineering and operations. He has a deep understanding of the total process of device development, manufacturing, costing, and continuous improvement. And, Mark has been awarded 13 patents including one for a porous extracellular matrix scaffold and method. His references shared with us that Mark led successful collaborations and teams of up to 75 in creating solutions based on new approaches and on better applications of existing component and device manufacturing technologies and processes. I cannot wait to learn from and work with such a seasoned medical device professional.

Alex Biris, NuShores’ Co-founder and Chief Technical Officer

Mark will report to NuShores’ CEO, Sharon Ballard and lead manufacturing engineering and production as well as lead NuShores’ establishment of medical device clean room facilities, one of only a handful of such in Arkansas.

Mark is a perfect fit for a small but fast-paced life sciences venture such as NuShores. His references told me that Mark consistently got more done with less. He is skilled in quickly and accurately diagnosing problems and challenges and resolving issues despite limited resources. And he understands the essential quality requirements of a medical device manufacturer in assuring manufacturability, testability and cost effectiveness.

Sharon Ballard, CEO

Mark brings more than 27 years of medical device manufacturing engineering and operations successes to NuShores. His career positions include Senior Manager Manufacturing Process Development at Medtronic Spine & Biologics, and Senior Manufacturing Engineer at DePuy Orthopaedics. He also held the position of Director of Manufacturing at several other innovation based medical device manufacturers. While at Medtronic’s Spine & Biologics, he achieved unblemished record of project successes.

Larger product launches at Medtronic to introduce new generation products could exceed 5,000 part numbers, 100,000 implants and instruments, and an overall launch value of $100M. I established a PMO department that met PMI standards, tracked internal manufacturing and external supply from venders, moved resources when needed, and ensured timely and accurate project communications. I achieved 15 for 15 in product-launch projects successes over a two year period. I am honored and excited to be a part of this revolutionary bone regeneration technology and to join a team that has developed this groundbreaking medical device as we manufacture the NuCressâ„¢ bone void filler scaffold product and other products based on this new technology.

Mark Pelo, Manufacturing Manager

About NuShores Biosciences LLC

NuShores’ vision is to improve the quality of life for people globally and to compete successfully in the bone and tissue regenerative materials industry. Early studies suggest that NuShores’ licensed, patented technology could deliver improved solutions for bone regeneration while cutting healthcare costs, lowering treatment risks and reducing healing times. Research results show that NuShores’ NuCress™ scaffold could offer a number of benefits that to date not achieved by currently marketed bone regeneration products, therefore promising to bring better treatment outcomes to millions of people with severe bone injuries. NuShores has the exclusive, global license from University of Arkansas Little Rock to commercialize university owned patented and patent-pending technologies.


Click here for more information about Mark Pelo


For more information on NuShores go to nushores.com

Share

They’ve Said About US

  • I am delighted to be working with such a wonderful team on lifechanging technologies and applications.  It is an honor to be along for the journey.

    James G. Wetrich
    Fellow of the American College of Healthcare Executives
  • I am honored to serve on the advisory board for NuShores Biosciences LLC. I look forward to opportunities to contribute to your efforts with my experience and lessons learned in the areas of science – technology planning and commercialization, and to assist in the clinical aspects to make it available to patients as soon as possible.

    C. Lowry Barnes MD
    Professor and The Carl L. Nelson, M.D. Distinguished Chair in Orthopaedic Surgery at UAMS
  • It is a rare opportunity to be able to support the historic scientific discoveries licensed to NuShores from UA Little Rock that will have a significant positive impact on public health and clinical practices.  I am blessed to be able to participate with NuShores team in maturing such scientific breakthroughs to commercial success

    Andrew G. Kumpuris
    Founder and Advisor
  • The NuShores group has assembled a very strong development team under Dr. Biris and the operational depth needed to bring their novel materials to the market.  I am very excited to be contributing to NuShores and Alex’ team.

    Mike Douglas PhD
    Executive Director Texas Life Science Collaboration Center
  • I am pleased to serve on the NuShores’ Advisory Board and look forward to contributing to their venture’s product successes.  There is a need for their innovative NuCressâ„¢ bone void filler that has potential use in my areas of medical practice.  I look forward to working with the NuShores team in accomplishing the scientific, regulatory and development milestones to make such a product available to physicians and their patients

    James Y. Suen MD
    Professor and Chairman of the Department of Otolaryngology – Head and Neck Surgery at University of Arkansas Medical Sciences
  • I am very excited to work with the team at NuShores in the development of an enabling technology in tissue regeneration.  I have worked with the group for some time now and have the greatest respect for their approach to the challenge and the quality of their research.  I believe that the rigor behind their work is world class and will be regarded as a new standard of care in repairing bone loss.

    Jeff Skiba PhD
    Founder of Vomaris Innovations Inc.
  • The opportunity to serve on the board of NuShores is exciting and thought-provoking.  As an active member of the scientific community with a specific interest in orthopedics, the ongoing research is especially relevant and exciting for me.  I am delighted to have to opportunity to help such a robust and creative group move their technology and research efforts forward

    Larry Suva PhD
    Professor and Department Head Texas A&M University

Contact Us

Send us a message at your convenience

Send Message

Search

Follow Us

  • LinkedIn

READ OUR FCOI

Contact Info

  • NuShores Biosciences LLC
  • 1523 South Bowman St. Suite 3-H, Little Rock, Arkansas 72211
  • 866-NUCRESS
  • info@nushores.com
  • nushores.com

In the News

  • NuShores receives additional funding for biomedical manufacturing automation to by US Army
  • NuShores Biosciences receives commercialization program funding for NuCressâ„¢ bone filler scaffolds
  • NuShores welcomes a new Quality and Regulatory medical device professional to Little Rock

Awards


© 2025 —NuShores Biosciences LLC

Prev Next